Change in Seizure Incidence in Febrile Children With COVID-19 in the Era of Omicron Variant of Concern.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of the Pediatric Infectious Diseases Society"
DOI: 10.1093/jpids/piac085
Abstract: In this single-center retrospective observational study, we report that the incidence of seizures in febrile children with COVID-19 was significantly higher in the Omicron era than in the pre-Omicron era (14.6% vs 1.7%, P read more here.
Keywords: children covid; omicron era; omicron; incidence ... See more keywords
Real world effectiveness of tixagevimab/cilgavimab (Evusheld) in the Omicron era
Sign Up to like & getrecommendations! Published in 2022 at "PLOS ONE"
DOI: 10.1371/journal.pone.0275356
Abstract: Background: Pre-exposure prophylaxis for COVID-19 with tixagevimab/cilgavimab (T/C) received Emergency Use Authorization (EUA) based off of results from a clinical trial conducted prior to the Omicron variant. Its clinical effectiveness has not been well described… read more here.
Keywords: omicron era; covid; tixagevimab cilgavimab; effectiveness ... See more keywords
COVID-19 in a Pre-Omicron Era: A Cross-Sectional Immuno-Epidemical and Genomic Evaluation
Sign Up to like & getrecommendations! Published in 2023 at "Vaccines"
DOI: 10.3390/vaccines11020272
Abstract: The seventh human coronavirus was discovered and reported primarily in Wuhan, China. After intense seasons with repercussions in all areas of humanity, the pandemic demonstrates a new perspective. In Brazil, the pandemic concept had impacts… read more here.
Keywords: omicron era; era cross; sectional immuno; cross sectional ... See more keywords
Efficacy and safety of sotrovimab for vaccinated or unvaccinated patients with mild-to-moderate COVID-19 in the omicron era.
Sign Up to like & getrecommendations! Published in 2022 at "Drug discoveries & therapeutics"
DOI: 10.5582/ddt.2022.01036
Abstract: Although sotrovimab, one of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibodies has been shown to be effective in patients with mild-to-moderate coronavirus disease 2019 (COVID-19) with risk factors, their efficacy in mRNA… read more here.
Keywords: omicron era; vaccinated unvaccinated; mild moderate; covid ... See more keywords